Cannabis smoking and dual use linked to higher respiratory risks

Cannabis vaping, smoking, and dual use and the onset of respiratory symptoms among US young adults.

American journal of preventive medicine • • Moderately Relevant
🤖

AI Summary

This longitudinal study examined respiratory health risks associated with cannabis consumption methods among 5,211 young adults (ages 18-24) with no prior respiratory conditions. Using data from the Population Assessment of Tobacco and Health Study collected between 2021-2023, researchers tracked individuals who reported cannabis vaping, smoking, or dual use at baseline and monitored them for the development of respiratory symptoms. The findings reveal a clear distinction between consumption methods: cannabis smoking alone increased respiratory symptom risk by 3 times, while the combination of smoking and vaping showed an even greater risk with 4.36 times higher odds of developing respiratory symptoms.

Notably, cannabis vaping alone did not show a statistically significant association with respiratory symptom onset, suggesting the inhalation of combustion byproducts from smoking—rather than vapor inhalation itself—may be the primary risk factor. However, the study revealed important nuances when tobacco use was excluded: dual cannabis vaping and smoking remained significantly associated with respiratory problems (aOR = 4.20), while cannabis smoking alone lost statistical significance. This suggests that the combination of repeated inhalation exposure, whether from tobacco co-use or cannabis polyuse, drives respiratory risk more than single-use methods.

The researchers emphasize these findings remain preliminary and highlight the need for more detailed data on specific cannabis products, consumption patterns, and frequency of use to better understand respiratory risks. While the study provides important public health information for young adults considering cannabis consumption methods, the absolute risk remains modest—only 2.3% of the study population developed new respiratory symptoms during the follow-up period. Understanding these patterns is crucial for harm reduction conversations, particularly as cannabis legalization expands and consumption methods diversify.

📄 Original Abstract

Many young adults vape and smoke cannabis, but it remains unclear whether dual use increases respiratory risks. This study analyzed the national longitudinal Population Assessment of Tobacco and Health Study. The sample included 5,211 young adults (ages 18-24) without prior respiratory or pulmonary conditions at wave 6 who completed wave 7. Multivariable logistic regressions examined longitudinal associations between baseline cannabis vaping and smoking with functionally important respiratory symptoms at follow-up, controlling for sociodemographics, other substance use, health conditions, obesity, and cannabis use frequency. Data were collected between 2021-2023 and analyzed in 2025. At baseline, 18.8% of young adults reported past 30-day cannabis vaping or smoking: 2.1% vaped only, 11.3% smoked only, and 5.3% both vaped and smoked. Overall, 2.3% reported onset of respiratory symptoms at follow-up. Compared with no cannabis vaping or smoking, cannabis vaping only was not associated with respiratory symptoms (aOR = 0.93, 95% CI, 0.20-4.43) while cannabis smoking only (aOR = 3.04, 95% CI, 1.64-5.64) and dual vaping and smoking (aOR = 4.36, 95% CI, 2.12-8.96) were associated with increased odds. Excluding young adults who used tobacco products at baseline, only dual vaping and smoking was associated with increased odds (aOR = 4.20, 95% CI, 2.03-8.70). Young adults who smoke cannabis, particularly those who smoke and vape, have higher odds of developing functionally important respiratory symptoms. However, these findings must be considered preliminary. More detailed data on cannabis use patterns, products, and co-use with tobacco are needed to better understand these associations.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.